stages preclinical testing early clinical trials learn lot best way advance genome editing therapies harvard geneticist george church involved early crispr work says working overcome problem lab explored species enzymes lieu cas9 wrote e mail looking approaches immune tolerance current gene therapies rely virus called adeno associated virus aav deliver gene editing tool cell people immunity aav excluded trials therapies immune systems likely clear treatment therapeutic effect strategy exclusion not work cas9 stanford porteus says adults exposed strep staph think surprising high proportion people immunity says stanford researchers looked found cas9 antibodies human cord blood samples presence shows human b